What an online marketing agency must settle before a film treatment
A brief asks for a polished 60-second manufacturing film. It gives the budget, launch date and product claims, but not the film’s principal use: silent paid social, sales follow-up or a trade-show screen. That omission changes the opening, the amount of evidence viewers can inspect, the role of sound and the deliverables worth buying. A script will not settle it; the film team would have to guess.
Consider a hypothetical campaign aimed at operations leads who need to understand an approved downtime-reduction claim. Engineering holds the supporting test evidence. Paid social is the primary placement; sales also wants a version that answers technical objections. That is enough to brief a treatment without prescribing one. It identifies the first viewer, the claim and the asset’s main job, while leaving the film team room to find a convincing form.
The agency or internal campaign lead should make that priority explicit. Grey Matter describes manufacturing purchases as involving engineering, procurement and operations, with different questions about capability, cost and risk. This is a promotional, sector-specific description, not a rule for every buying committee. Its useful implication is narrower: naming all three groups as the primary audience leaves the film team to choose whose question the film answers. Other reviewers may be better served by a technical sheet or a sales conversation.
Assign decision rights before requesting treatments. An agency is not required if an in-house lead already owns the campaign.
Technical and legal reviewers can withhold approval of an inaccurate claim or unauthorised material. They do not choose the campaign priority by default. The named client owner resolves competing requests and gives final sign-off once those required approvals are in place. If audience research, offer development or claim substantiation is missing, assign and scope that work rather than hiding it inside a production quote. A fuller production-brief checklist can help identify what must be settled before boards.
Buy the film’s job before deciding its form
In the hypothetical campaign, one treatment could establish the product’s relevance quickly, using visuals and text that remain intelligible without sound. Another could spend more time demonstrating the claim for a sales prospect. Neither is inherently better: each serves a different viewing situation.
Suppose the budget supports only one finished asset. The campaign owner should choose the primary job. If paid distribution takes priority, approve a focused sound-off film with a claim it can honestly explain in that placement, and direct technical questions to existing sales material. If sales follow-up matters more, approve the deeper proof-led film and revise the paid distribution plan. Narrowing the claim or changing the placement may be wiser than ordering a short cutdown that strips away essential evidence. If both jobs are essential, request a revised scope and price for two assets before approving either.
The treatment should test the creative answer to that decision, not reopen it. Leave the script, opening, visual language, exact runtime and choice of live action, animation or AI-assisted elements open unless a genuine constraint dictates them. Ask how each proposal makes the approved evidence credible in its intended placement. An animatic or sample shot can expose unreadable on-screen detail, an opening that takes too long, or a demonstration that depends on footage the business cannot supply. If neither treatment can explain the claim within the proposed runtime, change the runtime, claim or asset’s job explicitly. Production methods deserve the same scrutiny. Ask the specialist to identify footage, likenesses, music and other material requiring rights or permissions; technically sensitive shots; continuity checks; and the review point at which errors can still be corrected affordably. For any proposed version, ask where it will run and what distinct viewer need it serves. Digiday reports agency concerns about unused AI-generated variations and poor-quality placements. That supports a check on planned uses, not a presumption that AI-assisted production wastes money. Compare methods by accuracy, brand fit, rights, revision burden, schedule and achievable finish.
Treat changed campaign decisions as changes to scope
Agree how feedback will reach the film team: one campaign owner collects it, resolves contradictions and returns a consolidated decision. A technical reviewer may reject a performance claim; sales may explain why a prospect needs more proof. Neither request should silently replace the approved primary audience or add a deliverable.
After an audience, claim or placement is approved, changing it may require new evidence, revised boards, another edit and fresh approvals. Before asking for that work, have the owner decide what happens to budget, schedule or deliverables. The same rule applies if treatment review reveals that the original brief cannot work: record the changed decision, then revise the production scope. Set measurement expectations at the same handoff. Check separately whether the correct assets ran in the intended placements, whether viewers showed useful attention or engagement, and whether later commercial signals changed against a relevant baseline, if one exists. Name who will assess each signal and what the available data cannot establish. Views alone do not prove revenue impact in a purchase where the film is one of several touchpoints.
Before approving production, try one test: could the specialist propose two genuinely different treatments that both satisfy the same approved campaign brief? If not, a campaign choice may still be unresolved—or the brief may have dictated the film before anyone could test it.
